Name: | APOVAX, INC. |
Legal type: | Foreign Corporation |
Status: | Inactive |
Standing: | Good |
Profit or Non-Profit: | Profit |
File Date: | 15 Aug 2001 (24 years ago) |
Authority Date: | 15 Aug 2001 (24 years ago) |
Last Annual Report: | 07 Jul 2014 (11 years ago) |
Organization Number: | 0520961 |
ZIP code: | 40204 |
City: | Louisville |
Primary County: | Jefferson County |
Principal Office: | 1044 E. CHESTNUT STREET, LOUISVILLE, KY 40204 |
Place of Formation: | DELAWARE |
Plan Name | Plan Year | EIN/PN | Received | Sponsor | Total number of participants | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
APOIMMUNE, INC. | 2010 | 611392013 | 2011-08-01 | APOIMMUNE, INC. | 14 | |||||||||||||||||||||||||||||||
|
Plan administrator’s name | SAME |
Signature of
Role | Plan administrator |
Date | 2011-08-01 |
Name of individual signing | MARK DESALVO |
Valid signature | Filed with authorized/valid electronic signature |
File | View Page |
Three-digit plan number (PN) | 001 |
Effective date of plan | 2006-01-01 |
Business code | 541700 |
Sponsor’s telephone number | 5025691020 |
Plan sponsor’s address | 1044 E CHESTNUT ST, LOUISVILLE, KY, 402040000 |
Plan administrator’s name and address
Administrator’s EIN | 611392013 |
Plan administrator’s name | APOIMMUNE INC |
Plan administrator’s address | 1044 E CHESTNUT ST, LOUISVILLE, KY, 402040000 |
Administrator’s telephone number | 5025691020 |
Signature of
Role | Plan administrator |
Date | 2010-05-27 |
Name of individual signing | APOIMMUNE INC |
Valid signature | Filed with incorrect/unrecognized electronic signature |
Name | Role |
---|---|
Steve Gailar | Chairman |
Name | Role |
---|---|
Haval Shirwan | Executive |
Name | Role |
---|---|
Haval Shirwan | Director |
Steve Gailar | Director |
Name | Role |
---|---|
KY SECRETARY OF STATE | Registered Agent |
Name | Action |
---|---|
APOIMMUNE INC. | Old Name |
Name | File Date |
---|---|
App. for Certificate of Withdrawal | 2014-07-09 |
Annual Report | 2014-07-07 |
Principal Office Address Change | 2013-05-31 |
Annual Report | 2013-05-31 |
Annual Report | 2012-06-08 |
Amendment | 2011-07-06 |
Annual Report | 2011-02-10 |
Annual Report | 2010-03-16 |
Annual Report | 2009-01-16 |
Annual Report | 2008-06-23 |
Contract Type | Award or IDV Flag | PIID | Start Date | Current End Date | Potential End Date | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DEFINITIVE CONTRACT | AWARD | HSHQDC11C00136 | 2011-09-29 | 2013-09-30 | 2013-09-30 | |||||||||||||||||||||||||
|
Obligated Amount | 431115.00 |
Current Award Amount | 644736.20 |
Potential Award Amount | 1083743.08 |
Description
Title | DIVISION: CHEMICAL&BIOLOGICAL PPA: CHEMICAL&BIOLOGICAL THRUST: AGRICULTURE PROGRAM: AG DEFENSE BASIC RESEARCH PROJECT: FAD VACCINES&DIAGNOSTICS PERFORMER: APOIMMUNE, INC. APPROPRIATION YEAR: FY11 (13 FUNDS) BUDGET AUTHORITY: THREE-YEAR R&D FUNDS PROJECT MANAGER: BRUCE HARPER LEAD SUPPORT STAFF: ROBERT ORR, 202-254-6606 ALC: 70-08-1513 APPS: 70130800 DESCRIPTION: THE PURPOSE OF THIS REQUISITION IS TO PROVIDE FUNDING FOR PHASE 1 OF THE APOVAX104 AS A NOVEL VACCINE FOR FOOT AND MOUTH DISEASE FOR $431,115 TO APOIMMUNE, INC. AS THEY ARE A SELECTED PERFORMER UNDER LRBAA 10-01-F054. |
NAICS Code | 541711: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY |
Product and Service Codes | AJ52: LIFE SCIENCES (APPLIED/EXPLORATORY) |
Recipient Details
Recipient | APOVAX, INC. |
UEI | LT59MH2NTJP1 |
Recipient Address | 1044 E CHESTNUT ST, LOUISVILLE, JEFFERSON, KENTUCKY, 402046033, UNITED STATES |
FAIN | Awarding Agency | Assistance Listings | Start Date | End Date | Description | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R41DK081296 | Department of Health and Human Services | 93.847 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | 2010-09-05 | 2012-08-31 | APOFASL AS A NOVEL TREATMENT FOR TYPE 1 DIABETES IN NONHUMAN PRIMATES | |||||||||||||||||||||
|
||||||||||||||||||||||||||
R43AI074176 | Department of Health and Human Services | 93.855 - ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH | 2008-09-01 | 2010-08-31 | APOVAX104-TB AS A NOVEL VACCINE FOR TUBERCULOSIS | |||||||||||||||||||||
|
||||||||||||||||||||||||||
R44AI071618 | Department of Health and Human Services | 93.855 - ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH | 2006-08-01 | 2010-07-31 | APOVAX104-HPV AS A NOVEL VACCINE FOR CERVICAL CANCER | |||||||||||||||||||||
|
Program | Program Status | Average Hourly Wage | Project Cost | Incentive Amount | Initial Jobs | New Jobs | Date of Action | Approval Type |
---|---|---|---|---|---|---|---|---|
SBIR/STTR | Inactive | - | $0 | $430,000 | - | - | 2010-01-01 | Final |
SBIR/STTR | Inactive | - | $0 | $100,000 | - | - | 2008-11-01 | Final |
SBIR/STTR | Inactive | - | $0 | $500,000 | - | - | 2008-10-01 | Final |
SBIR/STTR | Inactive | - | $0 | $100,000 | - | - | 2007-10-01 | Final |
SBIR/STTR | Inactive | - | $0 | $100,000 | - | - | 2007-03-01 | Final |
Sources: Kentucky Secretary of State